ZBD's controlling shareholder passively reduced its holdings due to bond conversion, with shareholding dropping to 59.87%Zhitong·Sep 19, 2025 at 03:49 AM603567+994.00%
ZBD Pharmaceuticals' shareholder Huzhou Saihan reduced its holdings, bringing its stake down to 5%Zhitong·Sep 11, 2025 at 03:54 AM603567+994.00%
ZBD: Net profit loss of 78.2899 million yuan in the first half of 2025Zhitong·Aug 27, 2025 at 03:50 AM603567+994.00%
ZBD: The conversion price of the convertible bonds held by the controlling shareholder will be adjusted from RMB 13.35 per share to RMB 12.35 per shareZhitong·Aug 20, 2025 at 03:14 AM603567+994.00%
ZBD: The approval notice for the listing application of fumaric acid lupatadine as a chemical raw material drug has been obtainedZhitong·Jun 25, 2025 at 05:11 AM603567+994.00%
Huafu Securities: The Chinese medicine sector is expected to improve quarter by quarter in Q2-3 of 2025. Pay attention to the possibility of including innovative drug varieties in this year's medical insuranceZhitong·Jun 22, 2025 at 10:33 PM688658+731.00%600566-439.00%
ZBD plans to acquire the remaining 49% equity of Guizhou Shennong Valley to integrate resourcesZhitong·May 28, 2025 at 02:57 AM603567+994.00%
ZBD's compound Qindan oral liquid drug clinical trial has been approvedZhitong·May 28, 2025 at 02:53 AM603567+994.00%
ZBD: In the first quarter of 2025, the net profit was 75.2954 million yuan, a year-on-year decrease of 74.33%Zhitong·Apr 29, 2025 at 06:23 AM603567+994.00%
ZBD: Ha ZBD received the approval notice for the drug supplement applicationZhitong·Apr 9, 2025 at 02:46 AM603567+994.00%
ZBD: The company's sale of 100% equity in Hulin Fangsheng has obtained a net financial gain of approximately 420 million yuanZhitong·Apr 1, 2025 at 03:57 AM603567+994.00%
ZBD: The application for the listing of hydrochloride paroxetine chemical raw materials has been approvedZhitong·Feb 13, 2025 at 03:42 AM603567+994.00%
The output value of traditional Chinese medicine material planting and processing will exceed 43 billion, and Chongqing will create the "Yuchan Traditional Chinese Medicine" brandZhitong·Jan 24, 2025 at 02:51 AM603567+994.00%
ZBD's subsidiary Fuma Suan Bisoprolol Tablets has obtained a drug registration certificateZhitong·Jan 13, 2025 at 01:39 AM603567+994.00%
125 companies received institutional researchZhitong·Jan 8, 2025 at 06:20 PM300498+7.00%301171+185.00%
